The levels of the five methylated nucleosides pseudouridine (C-Urd), 1-methyladenosine (1-MeAdo), 4 acetylcytidine (4-AcCyd), 1 methylinosine (1-MeIno) and 7 methylguanosine (7-MeGuo) resulting from RNA degradation were examined in the urine of rheumatoid arthritis (RA) patients. Of these five, 1-MeAdo and C-Urd were correlated with the active phase of the disease, while two others (4-AcCyd and 1-MeIno), which require further evaluation, appeared to be linked to the prognosis of the disease. As RNA turnover is closely associated with cell proliferation, including that of lymphocytes in RA, there may be a hitherto unsuspected benefit in measuring 1-MeAdo and C-Urd as biochemical markers of RA disease activity.
T pathophysiology of rheumatoid arthritis (RA) is still not well understood, but the process is characterized by the proliferation of immunocompetent cells within the synovial membrane leading to the pannus. This structure is potentially devastating for the joint cartilage in which the production of numerous toxic mediators occurs [1] . The determination of mediators like cytokines, degradative enzymes and collagen catabolites has been carried out, but the results of these studies provided only a partial estimation of the RA process [2] .
Evaluation of the magnitude of lymphocyte proliferation could provide a relatively simple procedure for assessing disease activity. It is well known that when cell proliferation takes place, certain genes have to be transcribed into RNA which, like all biological molecules, possesses a turnover time dependent on the efficiency of the protein synthesis machinery of the cell [3] . The fidelity of translation, however, is itself affected by the post-transcriptional modifications undergone by the mRNA. For instance, the capping of mRNAs adds a 7-methylguanosine (7-MeGuo) at the 5' end of the transcript by a 5':5' link, thereby allowing the specific binding of a protein which facilitates initiation of mRNA translation. If 7-MeGuo is found primarily in mRNA, other modified nucleotides (MN) are more prevalent in rRNA and sRNA. For example, it has been shown that pseudouridine (C-Urd) is found in tRNA or rRNA, while N2, N2-dimethylguanosine is primarily found in rRNA [4, 5] . When RNAs are degraded to nucleosides and finally to bases, the four normal bases are reutilized by the salvage pathway for de novo nucleotide synthesis. In the case of MN, they cannot be reused for the de novo synthesis and are directly eliminated in urine. It was, therefore, reasonable to undertake measurements of their urinary concentration in order to estimate total RNA turnover. Further, the concentration of specific MN should permit us to evaluate the turnover of each of the different RNA species [6] .
In cancer, these MN are excreted in higher amounts in affected patients than in healthy subjects and they are considered to be markers of severity [7] or relapse [8] . However, these estimations are difficult to perform routinely because of the need for high-performance chromatographic (HPLC) methods.
Since the pioneering work of Beiser et al. [9] , immunological techniques have been demonstrated to be as accurate as and more convenient than HPLC for a clinical approach [10] . Furthermore, these assays permit more than one MN to be monitored for a given neoplasm since several specific antibodies are available. Consequently, they allow a higher level of confidence to be reached in diagnosis or follow-up [11] . We present here the preliminary results obtained when the five MN were measured in the urine of 31 RA patients during a 12 month follow-up.
C-Urd, 1-methyladenosine (1-MeAdo), 4-acetylcytidine (4-AcCyd) and 1-methylinosine (1-MeIno) are known to stem from rRNA and tRNA, while mRNA production is partially related to 7-MeGuo. The excretion of four MN was significantly increased in RA patients when compared with the excretion measured in healthy subjects. Interestingly, the respective concentration of each MN was different from those observed for cancer or haemopathies. Correlations with RA parameters seem to indicate that C-Urd and 1-MeAdo could be used as markers of RA activity, while the determination of 4-AcCyd, and to a lesser extent 1-MeIno, would appear to be linked to the RA autoimmune process.
MATERIALS AND METHODS

Patients
In order to determine whether a simple morning sample of urine could reflect the 24 h production of each of the MN, 10 patients suffering from RA hospitalized for a check-up of their disease were asked to participate in a nyctemeral cycle study of MN excretion during 3 days. No change in their treatment was allowed during this period of time. A first aliquot was immediately taken from a freshly collected uring sample at 8.00 a.m. Two other samplings were performed at 4.00 p.m. and 10.00 p.m., while the 24 h urine collection was saved at 4°C until the day after the last aliquot was collected.
In a second step, 31 patients suffering from RA were successively examined as out-patients during a 12 month period to assess the significance of these determinations as biological markers of the RA process. Neither renal insufficiency nor neoplasia were detected during the time of the survey. The mean age of patients was 57 2 9 yr. The sex ratio was 3 women:1 man. All the patients were receiving a long-acting drug; five patients were on an i.m. gold regimen, seven patients were on other sulphydryl compounds, sulphasalazine was provided to seven others, while 12 patients took methotrexate distributed weekly (7.5-15 mg). Twenty-eight of these patients did not take any steroids, whilst two patients had a daily dose of 7-10 mg of prednisone. The last patient needed more elevated amounts of steroids (steroid pulse of 15 mg/kg) because of a flare-up of his disease (samples were collected 1 day before the pulse), but none of the 31 patients was allowed to change their DMARD regimen during the follow-up period except when a flare-up occurred.
The degradation of joints was rather moderate since only one patient was graded IV in the radiological Steinbrocker index. A total of 25% of patients presented as grade I, while half of them were classified as grade II and grade III was retained for the remaining quarter of patients.
Both clinical and biological assessments were performed on every patient at each visit. The Lee index was used to quantify the patient's abilities along with morning stiffness. The swollen joint counts and the Ritchie index were used specifically to assess the inflammatory activity. Over this period, the erythrocyte sedimentation rate (ESR) according to the Westergren method and C-reactive protein (CRP) levels (nephelometric technique, Behring) were used as biological markers of disease activity. Rheumatoid factors (RF) were quantified by the nephelometric method (Behring) and results are given in IU/ml. Active disease was then defined on the basis of three or more of these four criteria: morning stiffness (MS) lasting q45 min, a swollen joint count and a Ritchie index grading of q3 and 10, respectively, ESR q27 mm/h. This definition of activity corresponds to the one proposed by the Food and Drug Administration (FDA) for clinical evaluation of anti-rheumatic drugs, except for the tender joint count which was replaced by the Ritchie index.
All 31 patients were seen once, in addition, five were seen five more times, three were seen two more times and two were seen one more time during the 12 month period, so that in all 64 clinical and biological assessments were available. The five patients seen six times were followed over a 10-12 month period which also permitted a longitudinal study to be carried out.
Morning urinary samples were obtained together with blood samples at each visit. The 64 urine samples from the total population of RA were then aliquoted, centrifuged and stored at −50°C until determination.
The control population was chosen to present the same average age and gender ratio as the RA population. Twenty-seven individuals without a history of inflammatory disease provided early morning urine samples. Further, no statistical differences in the urine creatinine level were found between the two populations.
Urinary determination of the modified nucleosides
The production and characterization of monoclonal antibodies, as well as the immunoenzymatic technique, have been described in detail elsewhere [12] . Briefly, Balb-C mice were immunized by injection of the MN (which is not immunogenic alone) coupled to bovine serum albumin (BSA). Monoclonal antibody production was performed according to the hybridoma technique. The concentration of MN was determined by a solid-phase ELISA competition procedure. Anti-mouse immunoglobulins conjugated to peroxidase were used as second antibodies. Results are expressed as the ratio between the concentration of MN and urine creatinine (Jaffe´technique) in order to take into account potential variations of glomerular filtration (nmol/mmol).
Statistical analysis
The comparative analysis of the results obtained on RA patients and controls was performed using the non-parametric test (Kruskal-Wallis test or MannWhitney U-test) and variance analysis F-test. A value of P Q 0.05 was accepted as significant. The regression analysis allowed any correlation between the various parameters to be measured, but the level was set to 0.01 to reduce the major part of the type II error risk found in this particular statistical analysis [13] .
RESULTS
Determination of the convenient time for sampling
For each MN, determinations performed on samples collected at 8.00 a.m., 4.00 p.m. and 10.00 p.m. were compared with those obtained at the 24 h sample in a population of the 10 patients during three consecutive days (one comparison per day) using a variance analysis for small samples (Kruskal-Wallis test). No statistical differences were found between the results obtained on the morning sample and the others (Table I) . For convenience, then, 8.00 a.m. was chosen as the time for collecting the daily sample.
MN values in RA patients
MN measurements performed on urine samples from patients with various types of solid cancers or haemopathies already published [10] were used as positive controls (Table II) . The levels of the differ- Urinary samples were collected at different times of the day from 10 women who suffered from RA during 3 days. 8.00 a.m., 4.00 p.m. and 10 p.m. were the times chosen for the different samplings. The determination of the five MN at each time for the 10 patients was compared to an aliquot collected on the 24 h diuresis of the same day. A Kruskal-Wallis non-parametric test was used for this statistical analysis. Results of day 2 are presented in the table. They were similar at day 1 and 3, and did not show any statistical difference between the different time of sampling and the 24 h aliquot for every MN. Thus, the morning sample was chosen for convenience during the rest of the study.
ent MN in RA patients are of the same order of magnitude as those found in cancer patients. Statistical comparison between RA patients and cancer patients was not carried out because of the discrepancy observed in age, renal dysfunction and cancer state. MN determinations in solid cancer patients, for instance, were performed at different times of the progression of the disease without taking into account the treatment or the tumour burden. This largely explains the large variance encountered in these populations and the moderate interest in statistically comparing the MN level with the RA population which was strictly defined like the cross-matched control population. In this latter comparison, the MN urinary concentrations were significantly increased in the RA population, except for 7-MeGuo and C-Urd. However, .. values were also larger in the RA population than in the controls, suggesting a weak specificity of the dosages or the presence of subpopulations in RA patients. This latter possibility prompted us to examine these MN determinations according to criteria like sex, long-acting drug intake and disease activity. Only the last factor was discriminatory according to the FDA disease activity score.
When the RA population was subdivided into inactive (15 samples) and active groups (16 samples) according to the disease activity criteria (Table III) , .. values were not more significantly elevated than those of ESR or CRP (as verified by the variance comparison, F-test). Using this partition, 4-AcCyd and 1-MeIno levels were significantly elevated in both the active and inactive subpopulation (P Q 0.0001/0.003 and P Q 0.0001/0.01, respectively). In the active group, C-Urd and 1-MeAdo concentrations were also significantly increased not only in comparison with the normal group (P Q 0.02 and P Q 0.008, respectively), but also with the inactive population where the C-Urd level was significantly increased (P Q 0.01) while the 1-MeIno level was just above the significance threshold (P Q 0.06). The inactive group showed no significant increase in the level of these two last catabolites in comparison with the results obtained in the control population. When the comparison was performed using Student's t-test on the whole population of 64 measurements (data not shown), these results were confirmed and amplified for C-Urd and 1-MeIno (P Q 0.001 and P Q 0.0001, respectively) between the active group (44 measurements) and the inactive group (20 measurements). 7-MeGuo did not show any significant difference between the two RA patient Urinary samples were collected from the 31 RA patients and were tested for the determination of five MN and compared with the results obtained in a control population cross-matched for age and sex ratio. Student's t-test was used. 1-MeIno, 1-MeAdo and 4-AcCyd were significantly increased in the RA population (P Q 0.03 to P Q 0.0007). Since the 7-MeGuo level appears higher in RA patients, the difference was not significant owing to the dispersion of the data. The same measurements were also performed in patients affected by different cancers [10] and haemopathies (personal results). The level of determination was of a similar magnitude when RA samples were compared to those found in neoplastic pathologies. DD, disease duration. Clinical and biological indices made at each consultation were used to assess the level of activity of the RA process in the 31 RA patients. In 15 patients, the RA state was considered as inactive, while in 16 other cases it was classified as active. The comparison was then carried out between these two populations and controls for the five MN using the U-test of Mann and Whitney. On this basis, inactive RA was different only by the level of 4-AcCyd and 1-MeIno (P Q 0.0001 and P Q 0.01), while C-Urd and especially 1-MeAdo allowed the active population to be differentiated from the control (P Q 0.02 and P Q 0.008). The C-Urd level was also significantly increased in active compared to inactive RA (P Q 0.01). DD, disease duration; MS, morning stiffness; NSJ, number of swollen joints; ESR, erythrocyte sedimentation rate.
groups and the control population (Table III) . However, its insignificant increase in active disease along with the large .. (1.54 vs. 0.06) may be due to the very high levels found in some of the patients of this group, while in the non-active group the mean values were of the same magnitude as those in the control group. Table IV presents the matrix of correlations determined between various markers in the 31 RA patients. Results are given as the mean of the correlation coefficients r. C-Urd and 1-MeAdo were correlated with the RA activity parameters (MS, Ritchie index, ESR, P between 0.01 and 0.001). The magnitude of the correlation between these urinary markers and clinical indices of activity (MS, Ritchie, number of swollen joints) was usually less strong than that between these same markers and the classical biological ones (ESR and CRP, P Q 0.001). However, when correlations were done on the 64 samples, these differences were abolished (data not shown). In addition, C-Urd and 1-MeAdo were the markers most strongly correlated to the Lee index, which is an index which combines disease activity and disease progression (P Q 0.001). 4-AcCyd and 1-MeIno were strongly linked to the duration of disease and RF level (P between 0.01 and 0.001). 7-MeGuo did not correlate with any of the above indices.
Correlation with the different clinical and biological parameters of the disease
Follow-up study
Five patients were followed during a 12-month period. Among them, two subjects endured significant flare-ups of the disease (Fig. 1) . In these two patients, 1-MeAdo and to a lesser extent C-Urd (data not shown) variations followed the disease activity (represented by the Lee index on the figures). 4-AcCyd, 1-MeIno and 7-MeGuo determinations did not present any correlation with any of the parameters measuring The correlations were carried out between the five MN and the different clinical and biological parameters of the 31 RA patients. C-Urd and 1-MeAdo were rather strongly correlated to disease activity markers (MS, Ritchie index, ESR and CRP), while 1-MeIno and 4-AcCyd were rather linked to disease characteristics like disease duration or rheumatoid factors. P Q 0.05 if r q 0.38; P Q 0.01 if r q 0.448; P Q 0.005 if r q 0.501; P Q 0.001 if r q 0.57. ***No correlation. F. 1.-Five patients were followed during a 12 month period (see Materials and methods). Among them, two presented a flare-up of the disease (see the Lee index curve on patients 1 and 3). 1-MeAdo and to a lesser extent C-Urd (data not shown) levels were strongly linked to the degree of disease activity since no parallel could really be observed between the levels of 1-MeAdo in patient 1 and patient 3 and the activity state. The lines represent the extent of the normal value of 1-MeAdo as defined in the control population. (see Table  III control). Note that the 1-MeAdo values tend to be normal when the flare-up is controlled. In contrast, 4-AcCyd did not follow the Lee index curve and remains largely above the normal value of this metabolite. The hatched rectangle below patients 1 and 3 represents the duration of the flare up.
several MN, as measured by our ELISA procedure, was significantly increased in RA patients when compared with controls, except for 7-MeGuo. Further, MN levels in RA patients deserve to be compared with the results obtained in neoplasia. Indeed, in carcinomas, the urinary excretion reaches similar orders of magnitude (Table I; [10, 11] ). In haemopathies, C-Urd, 1-MeIno [14] , 4-AcCyd and 7-MeGuo (J. G. Tebib, unpublished results; Table I ) levels are twice as high as those measured in RA patients. However, when the RA disease is active, this difference decreases, especially for C-Urd and for 4-AcCyd. Of interest is the increase in 1-MeAdo excretion which is strongly increased during flare-up, contrary to what is observed in various solid cancers or haemopathies ( [10] ; J. G. Tebib, unpublished results). These comparisons deserve two comments. First, nucleotide metabolism in the RA process is high since the production of several MN is significantly increased when compared with that observed in controls. Furthermore, the respective concentrations of some MN in RA were found to be as high as or even higher than those detected in neoplasia. Second, the pattern of MN excretion is different between these two latter populations, suggesting that there may be a difference between neoplastic dedifferentiation and the autoimmune activation which could be detected at the level of nucleotide metabolism. Moreover, when these assays were performed on 27 patients with spondyloarthropathies, only 4-AcCyd was significantly elevated (data not shown), enhancing the hypothesis of a possible pattern of production of MN specific for a given disease.
The .. values of the different MN measurements were usually larger in RA patients compared to controls, suggesting either a weak sensitivity of these measurements or an inhomogeneous distribution of the RA population. The second hypothesis was tested using the RA population separated according to different parameters. Duration of disease and radiological degradation did not improve the magnitude of .. as well as the intake of disease-modifying drugs, even when different subclasses were made on the basis of treatment or clustering of the RA population into two classes (with or without methotrexate). The only discriminant factor was disease activity. Indeed, both in inactive and active RA, the .. value in the MN determination was not significantly increased above that obtained in the control population (except for 7-MeGuo in the active RA patient group). Moreover, using this partition, 1-MeIno and 4-AcCyd were significantly increased in both RA subclasses, while C-Urd and 1-MeAdo were only elevated in the active group. Then, the larger magnitude of the .. observed in RA patients may be explained by the variation of disease activity from one patient to another.
To go further, the existence of correlations between MN concentrations and events which occurred during the course of the disease was then tested by a statistical study performed on the 31 patients of the initial population. disease activity, RF production or disease disability. In the three other patients, similar results were found, but were less meaningful, most probably because the disease activity was less intense.
DISCUSSION
The pathophysiological process of RA is not well understood, but the various mechanisms of activation of the immune system should proceed, at least in part, by an overproduction of mediators [1] . In this study, we hypothesized that this activation could also accelerate the turnover of RNA, thereby influencing the protein synthesis machinery. Our preliminary findings are in agreement with this possibility since the excretion of This study showed clearly that C-Urd and 1-MeAdo were strongly linked to the parameters measuring disease activity. They were less correlated with it than ESR and CRP when the Ritchie index was used, but at the same time they presented the best correlation with the Lee index which reflects more globally the activity state in patients having a rather limited destruction of the joints (three-quarters of the patients were classified as stage I or II). Moreover, of the five patients seen at least three times during the 1 yr follow-up, two patients presented a flare-up of the disease (Fig. 1) . In these two cases, C-Urd and especially 1-MeAdo dramatically followed the disease outcome. Thus, a simple ELISA test performed on an aliquot of untreated urine could help the clinician to appraise disease activity. C-Urd and 1-MeAdo are the catabolites of rRNA and tRNAs, and their increase appears meaningful as a signal of cellular activation.
1-MeIno and 4-AcCyd appeared to be linked to disease duration and RF level. They allowed RA patients to be differentiated from controls regardless of the activity state of the disease. Since these two MN also come from the catabolism of rRNA and tRNA, one can speculate that they could represent more specific catabolic products found in activated T or B cells which need to be studied. The possibility of quantifying the accurate turnover of various RNAs would help this type of investigation. The 7-MeGuo assay was non-informative. Indeed, this MN was not associated with any parameter included in this study and its .. values in active RA patients were strongly increased, suggesting a possible more complex linkage with the RA process. This compound represents at least partially the catabolism of mRNAs and one can speculate that the RA process may use more translation than transcription since MN from tRNA are significantly increased, while the more specific MN of mRNA catabolism is not.
In summary, MN determination in RA is of interest for at least two reasons. (i) These determinations proved that the autoimmune and inflammatory responses present the same degree of RNA catabolism as those depicted in some neoplastic processes. (ii) Two of these metabolites first appear as potential markers of disease activity and two others are linked to the RA process since they correlate with the duration of disease and RF production. Should these results be confirmed in a larger population, the inclusion of a variable like drug intake, degree of joint destruction or estimated pannus mass, should permit both of these determinations to be used as a non-invasive method for quantifying disease activity. 4-AcCyd and 1-MeIno presented different patterns, suggesting a different way of production which may be linked more tightly to the RA process. This unexpected result deserves to be confirmed with determinations of the differential production of RNAs, before attempting to use these two determinations as prognostic markers of the disease, as some are in neoplasia.
